Related Experiment Videos
Is transdermal nicotine associated with cardiovascular risk?
G A Thomas1, S V Davies, J Rhodes
1Department of Gastroenterology, University Hospital of Wales, Cardiff.
Journal of the Royal College of Physicians of London
|September 1, 1995
Summary
Transdermal nicotine reduced plasma fibrinogen levels in ulcerative colitis patients. This study explored nicotine
Area of Science:
- Gastroenterology
- Pharmacology
- Cardiovascular Medicine
Background:
- Ulcerative colitis (UC) management often involves maintenance therapy.
- Transdermal nicotine has been explored for its therapeutic potential in UC.
- Non-smokers with UC were studied to assess nicotine's effects.
Purpose of the Study:
- To investigate the impact of transdermal nicotine on hemostasis and serum lipids in non-smoking UC patients.
- To evaluate nicotine's efficacy as a maintenance therapy for ulcerative colitis.
- To assess potential cardiovascular risk factor modifications.
Main Methods:
- A controlled, double-blind trial involving 45 UC patients in remission.
- Random allocation to transdermal nicotine patches or placebo for 12 weeks.
- Measurement of hemostasis markers (platelet activation, endothelial damage, fibrinogen), white cell count, and serum lipids.
Main Results:
- Transdermal nicotine significantly reduced plasma fibrinogen levels.
- No significant effects were observed on markers of platelet activation or endothelial damage.
- White cell count and serum lipids remained unaffected by nicotine treatment.
Conclusions:
- Transdermal nicotine may beneficially affect plasma fibrinogen in UC patients.
- Further research is warranted to explore nicotine's potential influence on cardiovascular risk factors.
- Nicotine's role in UC maintenance therapy requires additional investigation.